Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2043)	2/27/2017 3:02:35 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

Beginning of the end between Sanofi and REGN, or "end of beginning"?: (whatever, the sooner the better) mediaroom.sanofi.com Sanofi and Lonza Enter into a Strategic Partnership to Establish a Large-Scale Biologics Production Facility - The large-scale facility, to be built in Visp, Switzerland, will be established through a joint venture with an initial investment of around CHF 290 million (€ 270 million) shared equally between Sanofi and Lonza - - The strategic partnership leverages Lonza's expertise in large-scale mammalian cell culture [1] facilities alongside Sanofi's strength in developing and launching biologics based treatments to address patient needs - The partnership provides both Sanofi and Lonza with substantial flexibility in an innovative setup: Each party will share the available capacity in line with their equity shareholding in the joint venture. Sanofi will have additional access to bio-manufacturing capacity to support increasing demands for their portfolio of biologic therapeutic products, should they require it. Lonza will be free to market their share of capacity, if not required by Sanofi, and will also market unused Sanofi capacity, where available. Lonza will construct the facility and will support the joint venture in its operation of the facility.